Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled eight people in total, split into two groups. Five participants received the treatment by injection under the skin only (Cohort 1), and three received it first through a drip into a vein and then by injection under the skin (Cohort 2). The trial was looking at a condition involving inflammation inside the eye (uveitis), and the main thing it set out to measure was how many people in each group showed a "treatment response" by Week 16 — meaning their eye inflammation had settled down according to specific criteria for things like fluid leakage and cell activity in the eye. One person in each group did not complete the study. The reported data shows that by Week 16, all participants who completed the study met the criteria for a treatment response — that was 4 out of 5 in Cohort 1 and 2 out of 3 in Cohort 2. For vision (measured as the number of letters read correctly on an eye chart), the reported changes from the starting point were small across both eyes and both groups at each check-up visit — generally shifting by only a few letters up or down at Weeks 4, 8, 12, 16, and 28. The reported data also shows that no participants in either group experienced a return of their uveitis symptoms at the Week 4, 8, or 12 check-ups; at Week 16, one participant in Cohort 1 was recorded as having a recurrence, while none in Cohort 2 did. It is worth noting that this was a very small trial with only eight participants, so the numbers on their own are limited in what they can tell us. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older.
- You are able to understand and sign a consent form agreeing to take part in the study.
- You have had a recent tuberculosis (TB) skin or blood test that came back negative (done within the last 3 months), or you had a latent (inactive) TB infection but have already completed a full course of preventive TB treatment.
- You have active inflammation inside at least one eye (specifically in the middle, back, or throughout the eye) that is serious enough to need treatment taken by mouth or injection into the body.
- You have at least some usable vision in at least one eye (able to see at least the top letter on a standard eye chart, or 20/400 vision).
- You are willing and able to follow all the study procedures and attend required visits.
- If you are a woman who could become pregnant, you must not currently be pregnant or breastfeeding, and you must have a negative pregnancy test at the start of the study and agree to pregnancy testing throughout.
- If you could become pregnant or father a child, you must agree to use two reliable forms of birth control throughout the study and for six weeks after your last dose (acceptable methods include hormonal contraception, an intrauterine device (IUD), barrier methods with spermicide, or surgical sterilization — or your partner has had a hysterectomy or vasectomy, or you are completely abstinent).
Who may not be able to join:
- You currently have a significant active infection (one that requires treatment), including active tuberculosis or HIV.
- You have received a live vaccine (such as MMR or chickenpox vaccine) in the past six weeks, or are expected to receive one at any point during the study.
- You have received the BCG vaccine (a specific TB vaccine) within the past year, or are expected to receive it during the study or within one year after finishing the study treatment.
- You have been diagnosed with cancer (other than a certain type of common skin cancer called non-melanoma skin cancer) within the past five years.
- You have had steroid or anti-VEGF injections into or around your eye within the last six weeks.
- You have received a medication called rituximab in the past six months, or certain other biologic medications (such as infliximab, daclizumab, or adalimumab) in the past two months.
- You have received certain strong chemotherapy-type medications (called alkylating agents, such as cyclophosphamide or chlorambucil) within the last nine months.
- You have a known allergy or sensitivity to the study drug (ustekinumab) or any of its ingredients.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Experiencing a Treatment Response by Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.